The effect of eight weeks of interval training combined with vitamin E supplementation on plasma levels of betatrophin in men with nonalcoholic fatty liver disease

Document Type : Research Paper I Open Access I Released under (CC BY-NC 4.0) license

Authors

Department of Physical Education, , Ahv.C., Islamic Azad University, Ahvaz, Iran.

Abstract

Aim: The aim of the present study was to investigate the effect of eight weeks of interval training combined with vitamin E supplementation on plasma betatrophin levels in men with nonalcoholic fatty liver disease.

Method: 40 middle-aged men with nonalcoholic fatty liver disease, aged 45 to 60 years, were purposively selected and then randomly divided into 4 groups: interval training, vitamin E, interval training + vitamin E, and control group. The interval training group trained for eight weeks, three sessions per week. The vitamin E group took 400 mg vitamin E tablets daily, and the control group did not participate in any training or intervention program. Plasma betatrophin levels were measured by ELISA protein assay. One-way analysis of variance (ANOVA) was used to compare variables in the study groups. Data were analyzed at a significance level of 0.05 and using SPSS-23 software.

Result: The results showed that eight weeks of interval training alone and in combination with vitamin E resulted in a significant decrease in plasma betatrophin levels (P < 0.05), while vitamin E alone had no significant effect on the levels of this protein (P > 0.05).

Conclusion: According to the results of the present study, it is recommended that people with non-alcoholic fatty liver disease benefit from interval training alone or in combination with vitamin E to increase fat metabolism and consequently prevent their storage and accumulation, especially in liver tissue.

Highlights

According to the findings of the present study, it is recommended that people with nonalcoholic fatty liver disease use interval training alone or in combination with vitamin E supplementation to control fatty liver disease and, consequently, prevent its complications.

Keywords

Main Subjects

References

  • [1] Engin A. Non-alcoholic fatty liver disease. Obesity and Lipotoxicity. 2017:443–467.
  • [2] Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World journal of gastrointestinal pathophysiology. 2016;7(2):211-218.
  • [3] Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. BioMed Research International. 2020(1):402-409.
  • [4] Zhang R, Abou-Samra AB. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovascular diabetology. 2014;13(1):133-139.
  • [5] Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Scientific reports. 2014;4(1):5013-5018.
  • [6] Hu W, Shao X, Guo D, Hao H, Zhang Y, Xia M, et al. Relationship of serum betatrophin with nonalcoholic fatty liver in a Chinese population. PloS one. 2017;12(1): 170-178.
  • [7] Bellanti F, Villani R, Facciorusso A, Vend miale G, Serviddio G. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radical Biology and Medicine. 2017;111:173–185.
  • [8] Qi X, Guo J, Li Y, Fang C, Lin J, Chen X, et al. Vitamin E intake is inversely associated with NAFLD measured by liver ultrasound transient elastography. Scientific Reports. 2024;14(1):25-29.
  • [9] Keshavarz F, Anoushirvani S, Arazi H, Afroundeh R, Golpasandi H. The effect of HIFT with ginger extract supplementation on the levels of some antioxidant enzymes in men with non-alcoholic fatty liver. Research in Exercise Nutrition. 2025;3(3):12-1. Doi: https://doi.org/10.22034/ren.2025.143126.1081.
  • [10] Fakhraei Y, Cheragh Birjandi S, Yaghoubi A, Rezaeian N, Rezaei V. The effect of high-intensity interval training and ginger supplementation on poly ADP-ribose polymerase 1 (PARP-1) and sirtuin 1 (SIRT1) gene expression in male rats with nonalcoholic fatty liver disease. Research in Exercise Nutrition. 2025;4(1):74-61. Doi: https://doi.org/10.22034/ren.2025.143968.1112.
  • [11] Barron-Cabrera E, Soria-Rodriguez R, Amador-Lara F, Martinez-Lopez E, editors. Physical activity protocols in non-alcoholic fatty liver disease management: A systematic review of randomized clinical trials and animal models. Healthcare; 2023(14): 15-22.
  • [12] Sonmez A, Dogru T, Ercin CN, Genc H, Celebi G, Gurel H, et al. Betatrophin levels are related to the early histological findings in nonalcoholic fatty liver disease. Metabolites. 2021;11(7):425-431.
  • [13] ZHANG L, GAO F. Value of betatrophin in predicting nonalcoholic fatty liver disease. Journal of Clinical Hepatology. 2018:2631–2634.
  • [14] Morelli MB, Chavez C, Santulli G. Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders. Expert opinion on therapeutic targets. 2020;24(1):79–88.
  • [15] Thorp A, Stine JG. Exercise as medicine: the impact of exercise training on nonalcoholic fatty liver disease. Current hepatology reports. 2020;19(4):402–411.
  • [16] Stine JG, Long MT, Corey KE, Sallis RE, Allen AM, Armstrong MJ, et al. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease. Hepatology communications. 2023;7(4):101-108.
  • [17] Stine JG, DiJoseph K, Pattison Z, Harrington A, Chinchilli VM, Schmitz KH, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Official journal of the American College of Gastroenterology| ACG. 2022 (10): 143-149.
  • [18] Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. Treatment of nonalcoholic fatty liver disease: role of AMPK. American Journal of Physiology-Endocrinology and Metabolism. 2016;311(4): 730–740.
  • [19] Alex S, Boss A, Heerschap A, Kersten S. Exercise training improves liver steatosis in mice. Nutrition & metabolism. 2015;12(1):29-38.
  • [20] Cho J, Lee I, Kim D, Koh Y, Kong J, Lee S, et al. Effect of aerobic exercise training on non-alcoholic fatty liver disease induced by a high fat diet in C57BL/6 mice. Journal of exercise nutrition & biochemistry. 2014;18(4):339-352.
  • [21] Cintra DE, Ropelle ER, Vitto MF, Luciano TF, Souza DR, Engelmann J, et al. RETRACTED: Reversion of hepatic steatosis by exercise training in obese mice: The role of sterol regulatory element-binding protein-1c. Elsevier; 2012;27(6): 15-26.
  • [22] Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, et al. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2011;300(5): 874–883.
  • [23] Alves‐Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Comprehensive physiology. 2018;8(1):1–22.
  • [24] Stevanović J, Beleza J, Coxito P, Ascensão A, Magalhães J. Physical exercise and liver “fitness”: Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Molecular metabolism. 2020;32:1-14.
  • [25] Selen ES, Choi J, Wolfgang MJ. Discordant hepatic fatty acid oxidation and triglyceride hydrolysis leads to liver disease. JCI insight. 2021;6(2): 135-146.
  • [26] Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends in pharmacological sciences. 2017;38(7):649-665.
  • [27] Sabag A, Way KL, Sultana RN, Keating SE, Gerofi JA, Chuter VH, et al. The effect of a novel low-volume aerobic exercise intervention on liver fat in type 2 diabetes: a randomized controlled trial. Diabetes care. 2020;43(10): 71–78.
  • [28] Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative stress: harms and benefits for human health. Oxidative medicine and cellular longevity. 2017(1):84-93.
  • [29] Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. LWW; 2004 (6): 497-502.
  • [30] Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). International journal of molecular sciences. 2013;14(10):704-728.
  • [31] Ohtani N, Kawada N. Role of the gut–liver axis in liver inflammation, fibrosis, and cancer: a special focus on the gut microbiota relationship. Hepatology communications. 2019;3(4):456–470.
  • [32] Safdar A, deBeer J, Tarnopolsky MA. Dysfunctional Nrf2–Keap1 redox signaling in skeletal muscle of the sedentary old. Free Radical Biology and Medicine. 2010;49(10):1487–1493.
  • [33] Bataille A, Manautou J. Nrf2: a potential target for new therapeutics in liver disease. Clinical Pharmacology & Therapeutics. 2012;92(3):340–348.
  • [34] Vilar‐Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant‐free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71(2):495–509.
  • [35] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;362(18):1675–1685.

 

 

Files

History

  • Receive Date: 15 September 2025
  • Revise Date: 24 February 2026
  • Accept Date: 07 March 2026
  • First Publish Date: 07 March 2026

Share

How to cite

Statistics